<DOC>
	<DOCNO>NCT01526057</DOCNO>
	<brief_summary>In study , patient moderate severe rheumatoid arthritis treat methotrexate receive 2 intravenous treatment either PF-05280586 Rituxan ( Rituximab ) MabThera ( Rituximab ) . During course study , effect drug assess sampling level drug blood , blood cell count , compare level among different treatment . Safety , tolerability immunologic response also evaluate throughout .</brief_summary>
	<brief_title>A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors ( REFLECTIONS B328-01 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Confirmed diagnosis rheumatoid arthritis Meets Class I , II III ACR 1991 Revised Criteria RA seropositivity Stable dose methotrexate Inadequate response TNF inhibitor Any prior treatment lymphocyte deplete therapy History active TB infection Known screen test positive specific virus indicator viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>rituximab</keyword>
	<keyword>methotrexate</keyword>
	<keyword>anti-TNF</keyword>
</DOC>